“Pharma is under a lot of government and public scrutiny. This industry also runs on meetings. You put those two facts together, and you can see that a meeting can expose pharma to significant risk of enforcement activity if not done correctly,” said Geoffrey Levitt, vice president and chief counsel of Wyeth Pharmaceuticals, Collegeville, Pa., during his keynote address at the Second Annual Pharmaceutical Meeting Planners Forum. Levitt's comment encapsulated one of the meeting's themes: how ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only gain access to Front and Center, you'll get exclusive access to a large archive of premium content.

Already registered? here.